|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unexpectedly, the mRNA extracted from MM plasma cell hybridized with TNF- and LT-specific, as well as IL-1-specific probes, although the culture supernatants did not contain detectable TNF/LT biologic activity.
|
2665838 |
1989 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines.
|
2790197 |
1989 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transfection of the heavy chain-TNF gene into a myeloma derived cell line which was producing the light chain of the same antibody, allowed the isolation of a cell line secreting a fusion protein of the expected molecular weight and composition.
|
2065106 |
1991 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that the cytokine (IL-6, TNF-alpha and IL-1beta) and IL-Ra gene polymorphisms do not confer susceptibility to the development of MM.
|
10848780 |
2000 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals with polymorphisms associated with a high production of TNFalpha/LTalpha are at a significantly increased risk of developing MGUS and myeloma.
|
10920132 |
2000 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agents which act to inhibit TNFalpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.
|
11494147 |
2001 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that myeloma stimulates osteoclastogenesis by triggering a coordinated increase in the tumor necrosis factor-related activation-induced cytokine (TRANCE) and decrease in its decoy receptor, osteoprotegerin (OPG).
|
11562486 |
2001 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that regulatory polymorphisms of the TNF-alpha gene can affect TNF-alpha production and predict the outcome after Thal therapy, particularly in those MM pts who are genetically defined as "high producers" of TNF-alpha.
|
12200397 |
2002 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
These findings suggest that regulatory polymorphisms of the TNF-alpha gene can affect TNF-alpha production and predict the outcome after Thal therapy, particularly in those MM pts who are genetically defined as "high producers" of TNF-alpha.
|
12200397 |
2002 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF), another stimulator of myeloma cell growth, up-regulated the expression level of IL-21 receptor (IL-21R), and combinations of TNF and IL-21 gave synergistic effects on myeloma cell proliferation.
|
11986233 |
2002 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the involvement of the tumor necrosis factor-ligand family member, receptor activator of nuclear factor-kappaB ligand (RANKL), and its naturally occurring antagonist, osteoprotegerin (OPG), in MM biology.
|
14500379 |
2003 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The results showed that FGF-2, VEGF, IL-6r, and TNF-alpha were significantly elevated in MM patients in comparison to controls ( p<0.008) and were significantly higher in stage III disease in comparison to stages I and II ( p<0.03).
|
12574959 |
2003 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Studies have shown that enhanced TNF-alpha levels in myeloma patients correlated with aggressive disease.
|
15041705 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM.
|
14512299 |
2004 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study did not support our starting hypothesis; that high producer haplotypes at the TNF locus are associated with an increased risk of developing myeloma.
|
15842659 |
2005 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite a far lower incidence of PCM and CLL in the Chinese population compared with Caucasians, the rates of TNFalpha-308A were similar to those in Caucasians, both in the study and control populations.
|
17071494 |
2006 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For genes in which linkage disequilibrium was observed between multiple loci, MM risk was positively associated with the haplotype block covering part of the LTA*TNF complex (LTA -82C/-90G *TNF -1036C/-487G/-417G, OR = 1.63, 95% CI 1.02-2.16) compared with the most frequently occurring haplotype observed among controls (LTA -82A/-90A *TNF -1036C/-487G/-417G).
|
17315188 |
2007 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.
|
17927494 |
2007 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD70 is a TNF superfamily member whose normal expression is highly restricted but is aberrantly expressed in hematologic malignancies including non-Hodgkin lymphoma (NHL), Hodgkin disease, and multiple myeloma.
|
17038522 |
2007 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma.
|
18405969 |
2008 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, marrow stromal cells from p62(-/-) mice produced much lower levels of IL-6, tumor necrosis factor-alpha (TNF-alpha), and receptor activator of NF-kappaB ligand (RANKL) and supported MM cell growth and osteoclast formation to a much lower extent than normal cells.
|
19282458 |
2009 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand receptors, Fas-associated death domain-containing protein (FADD), procaspase-8, procaspase-10, c-Jun amino-terminal kinase and Bid were also recruited into lipid rafts on resveratrol incubation with MM and T-cell leukemia cells.
|
19561642 |
2009 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MM patients carrying the GA genotype (P=0.01) or GA+AA genotypes (P=0.02) at the TNF-α -308 polymorphism were associated with a reduced risk for MM.
|
20122728 |
2010 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Could age modify the effect of genetic variants in IL6 and TNF-α genes in multiple myeloma?
|
22387051 |
2012 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knock-down of XBP1 in MM patient BMSCs greatly compromised their increased VCAM-1 protein expression and IL-6 and RANKL secretion in response to TNFα and reversed their enhanced support of MM-cell growth and osteoclast formation.
|
22427205 |
2012 |